LDS/Medical Tests/Hereditary Peripheral Neuropathies Gene Mutation Panel, NGS

Hereditary Peripheral Neuropathies Gene Mutation Panel, NGS

A hereditary peripheral neuropathy gene mutation panel detects mutations related to an inherited group of clinically and genetically heterogeneous peripheral nerve disorders that exhibit progressive degeneration of muscles in the extremities and loss of sensory function. These include hereditary motor and sensory neuropathy (usually called Charcot-Marie-Tooth disease: CMT), distal hereditary motor neuropathy (dHMN), hereditary sensory autonomous neuropathy (HSAN), hereditary neuropathy with a liability to pressure palsy (HNPP), and congenital hypomyelinating neuropathy (CHN).

Charcot-Marie-Tooth (CMT) is a group of sensory motor neuropathies due to mutations in genes whose protein products are found in myelin and/or axonal structures in peripheral nerves. These disorders usually start in childhood or the teenage years with distal motor weakness and sensory disturbances that is slowly progressive. Patients often develop feet deformities and less commonly other skeletal findings such as scoliosis. Additional manifestations may include deafness, optic atrophy or pyramidal signs. The severity of the disease is highly variable, ranging from almost asymptomatic adult patients to severely disabled children. Based on histopathological and electrophysiological criteria, CMT is further categorized into CMT type 1, or demyelinating type (CMT1/HMSN1), and CMT type 2, or axonal type (CMT2/HMSN2). While CMT type 1 is associated with reduced nerve conduction velocities, correlated to decreased myelination of the peripheral nerves, CMT type 2 is characterized by decreased amplitudes of motor and sensory nerve action potentials, related to primarily axonal loss in the peripheral nerve fibers. Although CMT is genetically heterogeneous the vast majority of cases are due rto mutations in four genes: PMP22, MPZ, GJB1 and MFN2. The most common form of the disorder, CMT-1, which accounts for 40% of CMT cases is caused by duplication of the peripheral myelin protein-22 (PMP22) gene.

Distal hereditary motor neuropathies (dHMN) are a group of disorders that affects neurons in the spinal cord. It is characterized by length-dependent, slowly progressive motor neuropathies with variable nerve conduction velocities. The symptoms include progressive weakness and atrophy of the distal muscles, foot deformities, and decreased reflexes. dHMN are subdivided into 11 subtypes based on inheritance pattern and clinical features and include types 1-7, dHMN plus pyramidal signs, X-linked, congenital distal SMA, and Jerash type. These disorders are caused by mutations in BSCL2, BSCL2, GARS1, HSPB1, HSPB3 and HSPB8 genes.

Hereditary sensory and autonomic neuropathies (HSAN types 1-5) are inherited conditions that are less common than the primary hereditary motor and sensory neuropathies. HSAN type 1 is an autosomal dominant condition characterized by degeneration of dorsal root ganglion and motor neurons resulting in distal muscle wasting, sensory loss and variable neural deafness. It is due to mutations in either SPLTC1, SPLTC2, ATL1, DNMT1 or ATL3. HSAN type 2 is an autosomal recessive disorder that primarily affects the sensory neurons and impair sensations such as pain, temperature, and touch. Deep pain perception, the feeling of pain from injuries to bones, ligaments, or muscles, is especially impaired in people with HSAN. Patients experience recurrent fractures and infections of the digits leading to mutation of the fingers and toes in early adulthood. This disorder is caused by mutations in WNK1, RETREG1, KIF1A or SCN9A. HSAN type 3, due to mutations in ELP1, is associated with prominent autonomic disturbances including vomiting, defective lacrimation, hypotonia, decreased deep tendon reflexes, and hyperhidrosis. HSAN types 4 and 5 are similar clinically to HSAN2 but is caused by mutations in NTRK1 or NGF.

Hereditary neuropathy with liability to pressure palsies is an autosomal dominant disorder that affects peripheral nerves and is characterized by nerve palsies in areas prone to nerve compression or trauma. The most commonly affected nerves are the axillary, median, radial, ulnar, peroneal, and brachial plexus. Patients are predisposed to develop neuromas at the location of nerve. It is estimated to occur in 2 to 5 per 100,000 individuals. In approximately 80% of cases is caused by the deletion in one copy of the PMP22 gene.

Congenital hypomyelinating neuropathy (CHN) is considered to be a result of congenital impairment in myelin formation. Major symptoms may include respiratory difficulty, muscle weakness and incoordination, poor muscle tone (neonatal hypotonia), absence of reflexes (areflexia), difficulty in walking (ataxia), and/or impaired abilities to feel or move part of the body. It is caused by mutation in the MPZ gene.

Panel Components

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: AAAS, AARS, AIFM1, ATL1, ATL3, ATP7A, BICD2, BSCL2, CHCHD10, DCTN1, DNAJB2, DCTN1, DNAJB2, DNM2, DNMT1, DST, DYNC1H1, EGR2, ELP1, FBXO38, FGD4, FIG4, GAN, GARS, GDAP1, GJB1, GNB4, HARS, HINT1, HSPB1, HSPB8, IGHMBP2, INF2, KIF1A, LITAF, LMNA, LRSAM1, MED25, MFN2, MORC2, MPZ, MTMR2, NDRG1, NEFL, NGF, NTRK1, PDK3, PLEKHG5, PMP22, PRPS1, PRX, RAB7A, REEP1, RETREG1, SBF2, SCN11A, SCN9A, SH3TC2, SIGMAR1, SLC25A46, SLC52A2, SLC52A3, SLC5A7, SPG11, SPTLC1, SPTLC2, TFG, TRIM2, TRPV4, TTR, UBA1, VAPB, VRK1, WNK1, YARS, SPAST associated with hereditary peripheral neuropathy.

  • To confirm a diagnosis of a suspected inherited peripheral neuropathy i.e. Charcot-Marie-Tooth neuropathy (CMT)
  • To identify mutations within genes known to be associated with inherited peripheral neuropathy
  • For pre-conception planning for potentially at-risk individuals
  • For pre-implantation embryonic testing in potentially at-risk individuals
  • For predictive testing of at-risk family members and to determine which relatives are at risk

Positive: At least one known pathogenic variant or mutation (deletion or duplication) associated with hereditary peripheral neuropathy should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutation (deletion or duplication) or pathogenic variant in the genes tested

Next-generation sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Array comparative genomic hybridization (aCHG), Prenatal Testing and Preimplantation genetic Testing, nerve conduction studies, nerve biopsy.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • BMJ Open. 2018;8: e021632. [PMID: 30373780]
  • Curr Genomics. 2018;19: 412-419. [PMID: 30258273]
  • Mol Cells. 2016; 39: 382–388. [PMID: 27025386]
  • Ann Neurol. 2014;75: 255-65. [PMID: 24339129]
  • Sci Rep. 2014;4: 7286. [PMID: 25446378]
  • BMC Med Genet. 2013;14: 94. [PMID: 24053775]
  • Mol Neurobiol. 2013; 47: 673–698. [PMID: 23224996]
  • Ann. Neurol. 2011; 69: 22-33. [PMID: 21280073]
  • Am. J. Hum. Genet. 2004; 74: 1064-73. [PMID: 15060842]
  • Bell, C., & Haites, N. (1997). The Peripheral Neuropathies and Their Molecular Genetics. Advances in Genetics, 1–44. doi:10.1016/s0065-2660(08)60306-5
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1358/ Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PMP22#
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login